Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback